{"filing":{"accession_number":"0001178913-26-002797","cik":"0001607962","ticker":null,"company_name":"Lifeward Ltd.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"zk2635366.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1607962/000117891326002797/zk2635366.htm"},"classifications":[{"id":117,"accession_number":"0001178913-26-002797","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Keith D. Rose, M.D. as Chief Medical Officer, effective May 1, 2026. This is a material executive appointment to a senior leadership position. Dr. Rose's extensive background in medical affairs and clinical leadership across major pharmaceutical companies (Novocure, Ipsen, Jazz Pharmaceuticals, Indivior) demonstrates the significance of this hire to the Company's medical and clinical strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:16:56.062645+00:00","company_name":"Lifeward Ltd.","ticker":null,"filing_date":"2026-05-19"}]}